Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 10/31/18 | SEC-generated letter |
|
1 | ||
| 10/24/18 | Registration statement for specified transactions by certain issuers |
|
60 | ||
| 08/29/18 | Confidential treatment order |
|
1 | ||
| 08/13/18 | Quarterly report pursuant to Section 13 or 15(d) |
|
 |
60 | |
| 08/09/18 | Current report filing |
|
9 | ||
| 07/25/18 | Statement of changes in beneficial ownership of securities |
|
1 | ||
| 06/11/18 | Current report filing |
|
3 | ||
| 05/14/18 | Quarterly report pursuant to Section 13 or 15(d) |
|
|
50 | |
| 05/10/18 | Current report filing |
|
9 | ||
| 05/04/18 | Current report filing |
|
29 |